WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100765
Description: Semustine is a drug used in chemotherapy. It is structurally similar to lomustine, being distinguished from it only by an additional methyl group. It has been taken off the drug market for investigation of its cancerous effects, rated as IARC Group 1 carcinogen or a known carcinogen.
MedKoo Cat#: 100765
Chemical Formula: C10H18ClN3O2
Exact Mass: 247.10875
Molecular Weight: 247.72
Elemental Analysis: C, 48.48; H, 7.32; Cl, 14.31; N, 16.96; O, 12.92
Semustine is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: CCNU methyl, MCCNU, methyl CCNU, methylCCNU, MeCCNU
IUPAC/Chemical Name: N-(2-Chloroethyl)-N'-(4-methylcyclohexyl)-N-nitrosourea
InChi Key: FVLVBPDQNARYJU-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H18ClN3O2/c1-8-2-4-9(5-3-8)12-10(15)14(13-16)7-6-11/h8-9H,2-7H2,1H3,(H,12,15)
SMILES Code: O=C(NC1CCC(C)CC1)N(CCCl)N=O
The following data is based on the product molecular weight 247.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Kobiakov GL. [Clinical significance of mustoforan in management of malignant glioma]. Vopr Onkol. 2007;53(6):724-9. Review. Russian. PubMed PMID: 18416147.
2: Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001 Jan;24(1):19-38. Review. PubMed PMID: 11219485.
3: Kodaira S, Shatari T, Nozawa K. [Recent advances is surgical adjuvant chemotherapy for colorectal cancer]. Gan To Kagaku Ryoho. 2000 Dec;27(14):2201-8. Review. Japanese. PubMed PMID: 11142163.
4: Saka M, Sasako M, Katai H, Sano T. [Current status and problem of adjuvant chemotherapy for curatively resected gastric cancer]. Gan To Kagaku Ryoho. 2000 Nov;27(13):2033-42. Review. Japanese. PubMed PMID: 11103234.
5: Hay JM, Msika S. [Radiotherapy and chemotherapy in the treatment of cancer of the rectum]. J Chir (Paris). 2000 Feb;137(1):13-5. Review. French. PubMed PMID: 10790613.
6: Tsukagoshi S. [Fundamental studies on the surgical adjuvant chemotherapy to support the clinical efficacies]. Gan To Kagaku Ryoho. 1997 Aug;24(10):1213-20. Review. Japanese. PubMed PMID: 9279339.
7: Cachat F, Guignard JP. [The kidney in children under chemotherapy]. Rev Med Suisse Romande. 1996 Dec;116(12):985-93. Review. French. PubMed PMID: 9026889.
8: [Choice of treatment in rectal cancer. Consensus Conference, Chamber of Commerce and Industry, Paris, December 1-2, 1994]. Ann Gastroenterol Hepatol (Paris). 1995 Sep;31(4):226-30, 233-6. Review. French. PubMed PMID: 7486820.
9: Shparik IaV. [Adjuvant chemotherapy of gastric cancer]. Klin Khir. 1995;(5):38-41. Review. Ukrainian. PubMed PMID: 8646632.
10: Mezger J. [Adjuvant therapy in colorectal carcinomas]. Dtsch Med Wochenschr. 1994 Dec 2;119(48):1663-8. Review. German. PubMed PMID: 7988367.
semustine is a methylated derivative of carmustine with antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)